FOXO4 (forkhead box O4; HGNC:7139, NCBI Gene ID 4303) is a human locus mapped to chromosome band Xq13.1 that encodes winged-helix Forkhead Box O4 transcription factor (505 aa). FOXO4 acts in oxidative stress JNK phosphorylation -> nuclear PML-body sequestration of p53 (TP53) & CDKN1A (p21) transcription in senescent cells, together with FOXO3 (Longevity Paralog Gene), FOXO1 (Metabolic Paralog Gene), and FOXO6 (Brain-Enriched Paralog Gene). Encodes the X-linked Forkhead box O4 transcription factor that tethers p53 in the nucleus of senescent cells to prevent apoptosis; targeted by the FOXO4-DRI senolytic peptide.
Oxidative stress JNK phosphorylation -> nuclear PML-body sequestration of p53 (TP53) & CDKN1A (p21) transcription in senescent cells
Clinical / Therapeutic Role
Target of the cell-penetrating FOXO4-DRI D-retro-inverso peptide senolytic that releases nuclear p53 to trigger apoptosis of senescent cells
Gene Structure & Expression
Genomic Organization & Cytogenetic Locus: 3-exon X-linked gene at chromosome Xq13.1 (originally identified as AFX1 at the t(X;11)(q13;q23) KMT2A/MLL translocation breakpoint in acute lymphoblastic leukemia), encoding a 505-amino-acid Forkhead transcription factor lacking the C-terminal extension of FOXO1/FOXO3.
Cellular & Tissue Expression Profile: Expressed at low basal levels in normal dividing cells across skeletal muscle, cardiac muscle, adipose tissue, and placenta, but dramatically up-regulated at both the mRNA and protein level inside irradiation-, chemotherapy-, and aging-induced senescent cells.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: While regulated canonically by insulin-AKT1 cytoplasmic export (phosphorylation at Thr32, Ser197, Ser262) and oxidative-stress JNK (MAPK8/9/10) nuclear import, in senescent cells FOXO4 localizes to nuclear promyelocytic leukemia (PML) bodies associated with persistent DNA-SCARS (DNA segments with chromatin alterations reinforcing senescence), where its Forkhead domain physically binds the transactivation domain of p53 (TP53)—driving CDKN1A (p21) transcription to maintain viability while preventing p53 from translocating to mitochondria to trigger BAX/cytochrome-c apoptosis.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Unlike Foxo1-null or Foxo3-null mice, Foxo4-knockout mice are viable and fertile without overt developmental defects, demonstrating that FOXO4 is largely dispensable in healthy young tissues while becoming a selective survival dependency of damaged senescent cells.
Therapeutic & Clinical Pharmacology: Inspired design of the landmark senolytic peptide FOXO4-DRI (a cell-penetrating D-retro-inverso peptide mimicking the FOXO4 p53-binding interface, Baar et al., 2017): FOXO4-DRI competitively disrupts the FOXO4-p53 complex inside senescent cells, releasing active p53 into the cytosol to induce selective intrinsic apoptosis of senescent cells and restore fur density, renal function, and physical stamina in aged and premature-aging models.